Take the Quiz
Guide · Updated October 16, 2026

Compounded vs Brand-Name Semaglutide

Same active ingredient. Brand: FDA-approved, $935–$1,349/mo list price or $149–$349/mo self-pay through NovoCare. Compounded: not FDA-approved, from $99/mo month to month. Quality verified through CoAs (USP <71>, USP <85>, HPLC potency).

EducationalUpdated October 16, 2026
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated October 16, 2026

Overview

Same active ingredient. Brand: FDA-approved, $935–$1,349/mo list price or $149–$349/mo self-pay through NovoCare. Compounded: not FDA-approved, from $99/mo month to month. Quality verified through CoAs (USP <71>, USP <85>, HPLC potency).

Related guides

Questions readers ask

What does brand-name Wegovy cost without insurance?

Through NovoCare self-pay, the Wegovy pill is $149, $199 or $299 a month depending on dose and the Wegovy pen is $349 a month, with new patients paying $199 for the first two fills through December 31, 2026 (read October 14, 2026).

Why should compounded semaglutide be the base form rather than a salt?

The FDA has warned against the salt forms semaglutide sodium and semaglutide acetate. The page advises using only semaglutide base, the peptide form, and checking that a compounded provider’s certificates of analysis cover sterility, endotoxin and HPLC potency testing.

Who makes compounded semaglutide compared with Ozempic or Wegovy?

Ozempic, Wegovy and Rybelsus are made by Novo Nordisk and are FDA-approved. Compounded semaglutide is based on the same molecule but is prepared by 503A or 503B pharmacies and is not FDA-approved; a licensed clinician decides whether either option fits you.

What does the top-rated provider charge for compounded semaglutide?

NexLife, rated 94/100 on our rubric, lists compounded semaglutide at $119 a month on a 12-month plan charged monthly or $139 month to month, the same at every dose (read October 14, 2026).

Primary sources

  1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  2. FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
  3. FDA: Compounding and the FDA — questions and answers
  4. FDA: Registered outsourcing facilities (503B)
  5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
  6. Wegovy (semaglutide) prescribing information, Novo Nordisk